

Surgical Innovations Group Plc
(the "Company")

Directorate changes and board succession planning

Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, announces the appointment of Jonathan Glenn as Senior Independent Non-executive Director and Chairman-designate of the Company with immediate effect.

Jonathan is an experienced board director and chairman, with an excellent track record in the medical device sector. He is currently Non-executive Chairman of Tissue Regenix plc, and was formerly Group CEO of Consort Medical Plc from 2007 to 2020, where he oversaw the £230m acquisition of a European contract development and manufacturing organisation. Jonathan led the business as CEO until its acquisition for £505m in 2020. Jonathan is a member of the Institute of Chartered Accountants in England and Wales.

He joins the board in anticipation of the upcoming retirement of Professor Mike McMahon, the founder of the Company, who retires from the board at the Annual General Meeting of the Company expected to take place on 27 June 2023.

Following an orderly handover process, Jonathan will succeed Nigel Rogers as Chairman upon announcement of the interim results expected in September 2023. Nigel has indicated his intention to remain on the board until an additional independent non-executive director has been appointed.

Chairman of the Company, Nigel Rogers, commented: *"It has been my great pleasure to lead the board since my appointment in 2015, and especially to work alongside Prof. Mike McMahon. As part of our planned succession arrangements, we are now delighted to have Jonathan joining us, and look forward to working with him to complete the transition in board composition for the next stage in the Company's evolution."*

A separate announcement will be made in due course giving formal notice of the Company's 2023 AGM.

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies:

Jonathan Martin Glenn (aged 54) is currently, or has during the past five years, been a director of the following companies:

Current directorships or partnerships	Previous directorships or partnerships
<ul style="list-style-type: none"> • Tissue Regenix Group plc • Tissue Regenix Holdings Limited • TRX Cardiac Limited • TRX Orthopaedics Limited • TRX Vascular Limited • TRX Wound Care Limited • Tissue Regenix Limited • Tissue Regenix Holdings Inc • Tissue Regenix Wound Care Inc • TRX Orthopedics Inc 	<ul style="list-style-type: none"> • AESICA BC Limited • AESICA Formulation Development Limited • AESICA Holdco Limited • AESICA M1 Limited • AESICA M2 Limited • AESICA Queensborough Limited • AESICA Trustee Company Limited • Bepak Europe Limited • Bepak Finance Limited • Bepak Holdings Limited • Binx Health Limited • Consort Medical Finance 2010 Limited • Consort Medical Finance Limited • Consort Medical Limited • Consort Medical plc • Integrated Aluminium Components Limited • Medical House (ASI) Limited • Medical House Products Limited • Pharmaron Manufacturing Services (UK) Ltd • The Medical House Group Limited • The Medical House Limited

Save as set out in this announcement there are no further details to be disclosed in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM Rule for Companies.

For further information please contact:

Surgical Innovations Group plc

David Marsh, CEO
Charmaine Day, CFO

www.sigroupplc.com

Tel: 0113 230 7597

Singer Capital Markets (Nominated Adviser & Broker)

Aubrey Powell / Oliver Platts

Tel: 020 7496 3000

Walbrook PR (Financial PR & Investor Relations)

Paul McManus / Lianne Applegarth

Tel: 020 7933 8780 or si@walbrookpr.com

Mob: 07980 541 893 / 07584 391 303

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.

Further information

Further details of the Group's businesses and products are available on the following websites:

www.sigroupplc.com

www.surginno.com

www.elementalhealthcare.co.uk

To receive regular updates by email, please contact si@walbrookpr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

